{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T08:30:06Z","timestamp":1793608206370,"version":"4.5.0"},"reference-count":68,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Rheumatology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.berh.2026.102135","type":"journal-article","created":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T21:41:17Z","timestamp":1775684477000},"page":"102135","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["State of the art and novel treatments in psoriatic arthritis"],"prefix":"10.1016","volume":"40","author":[{"given":"Simon","family":"Hackett","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hussein","family":"Al-Mossawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura C.","family":"Coates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.berh.2026.102135_bib1","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/s41572-021-00293-y","article-title":"Psoriatic arthritis","volume":"7","author":"FitzGerald","year":"2021","journal-title":"Nat Rev Dis Primers"},{"issue":"8","key":"10.1016\/j.berh.2026.102135_bib2","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1002\/art.21972","article-title":"Classification criteria for psoriatic arthritis (CASPAR)","volume":"54","author":"Taylor","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.berh.2026.102135_bib3","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s00296-020-04775-2","article-title":"Comorbidities in psoriatic arthritis: a systematic review and meta-analysis","volume":"41","author":"Gupta","year":"2021","journal-title":"Rheumatol Int"},{"issue":"1","key":"10.1016\/j.berh.2026.102135_bib4","first-page":"3","article-title":"Minimal disease activity as a treatment target in psoriatic arthritis: a review of the evidence","volume":"75","author":"Coates","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2026.102135_bib5","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2019-001083","article-title":"Treat-to-target in psoriatic arthritis: methods and necessity","volume":"6","author":"Dures","year":"2020","journal-title":"RMD Open"},{"issue":"4","key":"10.1016\/j.berh.2026.102135_bib6","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1136\/annrheumdis-2015-208617","article-title":"Treating to target in psoriatic arthritis: how to implement in clinical practice","volume":"75","author":"Coates","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.berh.2026.102135_bib7","article-title":"Persistence of biologic treatments in psoriatic arthritis: a population-based study in Sweden","volume":"4","author":"Geale","year":"2020","journal-title":"Rheumatol Adv Pract"},{"issue":"8","key":"10.1016\/j.berh.2026.102135_bib8","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1002\/art.22758","article-title":"The synovio-entheseal complex and its implications for understanding joint inflammation and damage in psoriatic arthritis","volume":"56","author":"McGonagle","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"10136","key":"10.1016\/j.berh.2026.102135_bib9","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1016\/S0140-6736(18)30830-4","article-title":"The pathogenesis of psoriatic arthritis","volume":"391","author":"Veale","year":"2018","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.berh.2026.102135_bib10","first-page":"288","article-title":"Mechanistic immunology of psoriatic disease","volume":"14","author":"McGonagle","year":"2018","journal-title":"Nat Rev Rheumatol"},{"issue":"4","key":"10.1016\/j.berh.2026.102135_bib11","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.immuni.2011.08.001","article-title":"Pivotal role of dermal IL-17\u2013producing \u03b3\u03b4 T cells in skin inflammation","volume":"35","author":"Cai","year":"2011","journal-title":"Immunity"},{"issue":"2","key":"10.1016\/j.berh.2026.102135_bib12","first-page":"935","article-title":"Treatment patterns, switching, and discontinuation in psoriatic arthritis patients receiving biologic therapy","volume":"8","author":"Mease","year":"2021","journal-title":"Rheumatol Ther"},{"issue":"6","key":"10.1016\/j.berh.2026.102135_bib13","first-page":"1069","article-title":"Predictors of response and drug survival in psoriatic arthritis patients treated with biologics","volume":"74","author":"Kristensen","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.berh.2026.102135_bib14","first-page":"21","article-title":"Patient preferences for treatment characteristics in inflammatory arthritis","volume":"76","author":"Gossec","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2026.102135_bib15","article-title":"Risk of candidiasis associated with interleukin-17 inhibitors: a real-world observational study","author":"Saunte","year":"2021","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.berh.2026.102135_bib16","unstructured":"European Medicines Agency (EMA). Janus kinase inhibitors (JAKi) referral. Amsterdam: European Medicines Agency. Available from:: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/referrals\/janus-kinase-inhibitors-jaki."},{"issue":"5","key":"10.1016\/j.berh.2026.102135_bib17","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1136\/annrheumdis-2013-204448","article-title":"Obesity is associated with a lower probability of achieving sustained minimal disease activity in psoriatic arthritis","volume":"74","author":"Eder","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2026.102135_bib18","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S0140-6736(15)61134-5","article-title":"Secukinumab in psoriatic arthritis (FUTURE 1 and FUTURE 2)","volume":"386","author":"McInnes","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.berh.2026.102135_bib19","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S0140-6736(13)60594-2","article-title":"Efficacy and safety of ustekinumab in patients with active psoriatic arthritis (PSUMMIT 1)","volume":"382","author":"McInnes","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.berh.2026.102135_bib20","first-page":"864","article-title":"Treatment response, drug survival, and predictors thereof in biologic-treated patients with psoriatic arthritis","volume":"77","author":"Glintborg","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2026.102135_bib21","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0140-6736(20)30265-8","article-title":"Guselkumab in patients with active psoriatic arthritis (DISCOVER-1 and DISCOVER-2)","volume":"395","author":"Deodhar","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.berh.2026.102135_bib22","first-page":"1280","article-title":"Efficacy and safety of combination induction therapy with guselkumab and golimumab in ulcerative colitis (VEGA)","volume":"388","author":"Sandborn","year":"2023","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.berh.2026.102135_bib23","doi-asserted-by":"crossref","first-page":"3173","DOI":"10.1093\/rheumatology\/keaf037","article-title":"The use of combination advanced therapies in psoriatic arthritis: results from a UK multicentre audit","volume":"64","author":"Jethwa","year":"2025","journal-title":"Rheumatology"},{"key":"10.1016\/j.berh.2026.102135_bib24","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1283251","article-title":"Dual targeted therapy in patients with psoriatic arthritis and spondyloarthritis: a real-world multicenter experience from Spain","volume":"14","author":"Valero-Mart\u00ednez","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.berh.2026.102135_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.672515","article-title":"From bed to bench and back: TNF-\u03b1, IL-23\/IL-17A, and JAK-dependent inflammation in the pathogenesis of psoriatic synovitis","volume":"12","author":"Silvagni","year":"2021","journal-title":"Front Pharmacol"},{"issue":"7","key":"10.1016\/j.berh.2026.102135_bib26","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.3390\/biomedicines10071485","article-title":"Pathogenesis of paradoxical reactions associated with targeted biologic agents for inflammatory skin diseases","volume":"10","author":"Miyagawa","year":"2022","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.berh.2026.102135_bib27","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1080\/19420862.2015.1111497","article-title":"Influence of molecular size on tissue distribution of antibody fragments","volume":"8","author":"Li","year":"2016","journal-title":"mAbs"},{"key":"10.1016\/j.berh.2026.102135_bib28","doi-asserted-by":"crossref","first-page":"4160","DOI":"10.1038\/s41591-025-03971-6","article-title":"Sonelokimab, an IL-17A\/IL-17F-inhibiting nanobody, for active psoriatic arthritis: a randomized, placebo-controlled phase 2 trial","volume":"31","author":"McInnes","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.berh.2026.102135_bib29","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.3389\/fimmu.2017.01603","article-title":"Nanobodies and nanobody-based human heavy chain antibodies as antitumor therapeutics","volume":"8","author":"Bannas","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.berh.2026.102135_bib30","unstructured":"MoonLake Immunotherapeutics. MoonLake immunotherapeutics starts phase 3 IZAR program [Internet]. Zug: MoonLake Immunotherapeutics;. Available from: https:\/\/ir.moonlaketx.com\/news-releases\/news-release-details\/moonlake-immunotherapeutics-starts-phase-3-izar-program."},{"issue":"5","key":"10.1016\/j.berh.2026.102135_bib31","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1093\/rheumatology\/keae580","article-title":"Deucravacitinib, a selective TYK2 inhibitor, in psoriatic arthritis: achievement of minimal disease activity components in a phase 2 trial","volume":"64","author":"Kavanaugh","year":"2025","journal-title":"Rheumatology"},{"key":"10.1016\/j.berh.2026.102135_bib32","unstructured":"European Medicines Agency (EMA). Otezla: EPAR \u2013 product information [Internet]. Amsterdam: European Medicines Agency; [cited 2026 January 30]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/otezla-epar-product-information_en.pdf."},{"key":"10.1016\/j.berh.2026.102135_bib33","doi-asserted-by":"crossref","first-page":"949","DOI":"10.2147\/PPA.S242336","article-title":"Treatment mode preferences in psoriatic arthritis: a qualitative multi-country study","volume":"14","author":"Aletaha","year":"2020","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.berh.2026.102135_bib34","series-title":"Poster presented at: European alliance of associations for rheumatology (EULAR)","article-title":"Icotrokinra, a first-in-class, targeted oral peptide, in participants with psoriatic disease: exploratory assessments from a phase 2 psoriasis study informing a phase 3 clinical program in psoriatic arthritis","author":"Merola","year":"2025"},{"key":"10.1016\/j.berh.2026.102135_bib35","series-title":"Zasocitinib landmark: advancing treatment for immune-mediated diseases [Internet]","year":"2025"},{"issue":"11","key":"10.1016\/j.berh.2026.102135_bib36","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1038\/s41591-023-02613-z","article-title":"Targeted depletion of TRBV9+ T cells as immunotherapy in a patient with ankylosing spondylitis","volume":"29","author":"Britanova","year":"2023","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.berh.2026.102135_bib37","doi-asserted-by":"crossref","first-page":"4767","DOI":"10.1038\/s41467-020-18513-6","article-title":"Single-cell sequencing reveals clonal expansions of pro-inflammatory synovial CD8 T cells expressing tissue-homing receptors in psoriatic arthritis","volume":"11","author":"Penkava","year":"2020","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.berh.2026.102135_bib38","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1134\/S1607672925700140","article-title":"The efficacy and safety of BCD-180, an anti-TRBV9+ T-cell monoclonal antibody, in patients with active radiographic axial spondyloarthritis: 36-week results from the phase 2 ELEFTA trial","volume":"522","author":"Nasonov","year":"2025","journal-title":"Dokl Biochem Biophys"},{"key":"10.1016\/j.berh.2026.102135_bib39","unstructured":"Immunitas Therapeutics. Immunitas therapeutics presents preclinical data on IMT-380, a first-in-class anti-CD161 antibody, at FASEB science research conference on autoimmunity [Internet]. Waltham (MA): Immunitas Therapeutics; [cited 2026 January 30]. Available from: https:\/\/www.prnewswire.com\/news-releases\/immunitas-therapeutics-presents-preclinical-data-on-imt-380-a-first-in-class-anti-cd161-antibody-at-faseb-science-research-conference-on-autoimmunity-302516527.html."},{"issue":"6","key":"10.1016\/j.berh.2026.102135_bib40","first-page":"815","article-title":"TWEAK, TL1A, and TNF-like cytokines: role in chronic inflammation and tissue remodelling","volume":"34","author":"Meylan","year":"2011","journal-title":"Immunity"},{"key":"10.1016\/j.berh.2026.102135_bib41","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/978-1-4419-6612-4_29","article-title":"Insights into TL1A and IBD pathogenesis","volume":"691","author":"Shih","year":"2011","journal-title":"Adv Exp Med Biol"},{"issue":"5804","key":"10.1016\/j.berh.2026.102135_bib42","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1126\/science.1135245","article-title":"A genome-wide association study identifies IL23R and TNFSF15 as susceptibility genes for inflammatory bowel disease","volume":"314","author":"Duerr","year":"2006","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.berh.2026.102135_bib43","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1189\/jlb.3RI0315-095R","article-title":"The TNF-family cytokine TL1A: from lymphocyte costimulator to disease co-conspirator","volume":"98","author":"Richard","year":"2015","journal-title":"J Leukoc Biol"},{"issue":"12","key":"10.1016\/j.berh.2026.102135_bib44","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa2314076","article-title":"Phase 2 trial of Anti-TL1A monoclonal antibody tulisokibart for ulcerative colitis","volume":"391","author":"Sands","year":"2024","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.berh.2026.102135_bib45","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/S2468-1253(25)00071-8","article-title":"Safety and efficacy of the anti-TL1A monoclonal antibody tulisokibart for Crohn's disease: a phase 2a induction trial","volume":"10","author":"Feagan","year":"2025","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"11","key":"10.1016\/j.berh.2026.102135_bib46","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1016\/j.cgh.2021.06.011","article-title":"Anti-TL1A antibody PF-06480605 safety and efficacy for ulcerative colitis: a phase 2a single-arm study","volume":"19","author":"Danese","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"9","key":"10.1016\/j.berh.2026.102135_bib47","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nrrheum.2014.105","article-title":"Treg-cell therapies for autoimmune rheumatic diseases","volume":"10","author":"Miyara","year":"2014","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"10.1016\/j.berh.2026.102135_bib48","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1136\/annrheumdis-2015-208456","article-title":"Autologous tolerogenic dendritic cells for rheumatoid and inflammatory arthritis","volume":"76","author":"Bell","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.berh.2026.102135_bib49","doi-asserted-by":"crossref","first-page":"20675","DOI":"10.1038\/s41598-022-24924-w","article-title":"Regulatory T cells in psoriatic arthritis: an IL-17A-producing, Foxp3intCD161 + ROR\u03b3t + ICOS + phenotype, that associates with the presence of ADAMTSL5 autoantibodies","volume":"12","author":"Pouw","year":"2022","journal-title":"Sci Rep"},{"issue":"10","key":"10.1016\/j.berh.2026.102135_bib50","first-page":"1839","article-title":"Tissue-resident memory T cells from psoriatic arthritis synovium produce IL-17A","volume":"74","author":"Leijten","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"21","key":"10.1016\/j.berh.2026.102135_bib51","first-page":"2037","article-title":"Immunological and clinical effects of low-dose interleukin-2 across autoimmune diseases","volume":"381","author":"Rosenzwajg","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.berh.2026.102135_bib52","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1146\/annurev.immunol.21.120601.141040","article-title":"Tolerogenic dendritic cells","volume":"21","author":"Steinman","year":"2003","journal-title":"Annu Rev Immunol"},{"issue":"2","key":"10.1016\/j.berh.2026.102135_bib53","doi-asserted-by":"crossref","first-page":"156","DOI":"10.3109\/08830180903281193","article-title":"Development of dendritic cell-based immunotherapy for autoimmunity","volume":"29","author":"Hilkens","year":"2010","journal-title":"Int Rev Immunol"},{"key":"10.1016\/j.berh.2026.102135_bib54","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1146\/annurev-immunol-031210-101322","article-title":"Inflammatory mechanisms in obesity","volume":"29","author":"Gregor","year":"2011","journal-title":"Annu Rev Immunol"},{"issue":"3","key":"10.1016\/j.berh.2026.102135_bib55","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s40744-020-00215-6","article-title":"Obesity and psoriatic arthritis: a narrative review","volume":"7","author":"Kumthekar","year":"2020","journal-title":"Rheumatol Ther"},{"issue":"6","key":"10.1016\/j.berh.2026.102135_bib56","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1136\/annrheumdis-2012-202812","article-title":"Weight loss and achievement of minimal disease activity in patients with psoriatic arthritis starting TNF-\u03b1 blockers","volume":"73","author":"Di Minno","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 2","key":"10.1016\/j.berh.2026.102135_bib57","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1136\/annrheumdis-2019-eular.1474","article-title":"Ixekizumab improves signs and symptoms of psoriatic arthritis regardless of sex, disease duration, or BMI: results from two phase 3 trials","volume":"78","author":"Eder","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.berh.2026.102135_bib58","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13075-019-1810-5","article-title":"Weight loss improves disease activity in patients with psoriatic arthritis and obesity: an interventional study","volume":"21","author":"Klingberg","year":"2019","journal-title":"Arthritis Res Ther"},{"issue":"12","key":"10.1016\/j.berh.2026.102135_bib59","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1002\/oby.21955","article-title":"Bariatric surgery and the incidence of psoriasis and psoriatic arthritis in the Swedish obese subjects study","volume":"25","author":"Maglio","year":"2017","journal-title":"Obesity"},{"issue":"1","key":"10.1016\/j.berh.2026.102135_bib60","first-page":"183","article-title":"Maintenance of lost weight and long-term management of obesity","volume":"102","author":"Hall","year":"2018","journal-title":"Med Clin"},{"key":"10.1016\/j.berh.2026.102135_bib61","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.berh.2026.102135_bib62","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.berh.2026.102135_bib63","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of action and therapeutic application of glucagon-like peptide-1","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell Metab"},{"key":"10.1016\/j.berh.2026.102135_bib64","series-title":"Impact of SGLT2 inhibitors and GLP-1 agonists on RA flares in patients on DMARD therapy","author":"Patel","year":"2025"},{"key":"10.1016\/j.berh.2026.102135_bib65","series-title":"Glucagon-like peptide-1 receptor agonists therapy is associated in improvement in psoriatic arthritis-related and metabolic outcomes: a retrospective analysis of two cohorts. Abstract 2687","author":"Eder","year":"2025"},{"issue":"1","key":"10.1016\/j.berh.2026.102135_bib66","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2025.103936","article-title":"Impact of GLP-1 analogues on immune-mediated inflammatory diseases: a systematic review","volume":"25","author":"Birda","year":"2026","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.berh.2026.102135_bib67","unstructured":"Eli Lilly and Company. Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together [Internet]. Indianapolis (IN): Eli Lilly and Company; [cited 2026 January 30]. Available from: https:\/\/investor.lilly.com\/news-releases\/news-release-details\/lillys-taltz-ixekizumab-and-zepbound-tirzepatide-used-together."},{"issue":"10429","key":"10.1016\/j.berh.2026.102135_bib68","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/S0140-6736(23)02649-1","article-title":"Abatacept in individuals at high risk of rheumatoid arthritis (APIPPRA): a randomised, double-blind, multicentre, parallel, placebo-controlled, phase 2b clinical trial","volume":"403","author":"Cope","year":"2024","journal-title":"Lancet"}],"container-title":["Best Practice & Research Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694226000203?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694226000203?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T08:15:58Z","timestamp":1793607358000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521694226000203"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":68,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1521694226000203"],"URL":"https:\/\/doi.org\/10.1016\/j.berh.2026.102135","relation":{},"ISSN":["1521-6942"],"issn-type":[{"value":"1521-6942","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"State of the art and novel treatments in psoriatic arthritis","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Rheumatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.berh.2026.102135","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102135"}}